Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedSep 23, 2015Hydromorphone 70 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1555-2015Class IITerminatedSep 23, 2015Hydromorphone 65 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1554-2015Class IITerminatedSep 23, 2015Hydromorphone 60 mg/ml + Bupivacaine 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1553-2015Class IITerminatedSep 23, 2015Hydromorphone 5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1552-2015Class IITerminatedSep 23, 2015Hydromorphone 40 mg/ml + Bupivacaine 40 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1551-2015Class IITerminatedSep 23, 2015Hydromorphone 40 mg/ml + Bupivacaine 20 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1550-2015Class IITerminatedSep 23, 2015Hydromorphone 30 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1549-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml + Bupivacaine 0.25 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1548-2015Class IITerminatedSep 23, 2015Hydromorphone 20 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1547-2015Class IITerminatedSep 23, 2015Hydromorphone 15 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1546-2015Class IITerminatedSep 23, 2015Hydromorphone 12.5 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1545-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml + Bupivacaine 10 mg/ml SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1544-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml + Baclofen 2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1543-2015Class IITerminatedSep 23, 2015Hydromorphone 10 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1542-2015Class IITerminatedSep 23, 2015Hydromorphone 1 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1541-2015Class IITerminatedSep 23, 2015Hydromorphone 0.25 mg/ml Intrathecal SolutionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1540-2015Class IITerminatedSep 23, 2015Hyaluronidase 175 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1539-2015Class IITerminatedSep 23, 2015Hyaluronidase 150 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1538-2015Class IITerminatedSep 23, 2015Hyaluronidase 150 units/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1537-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 35 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1536-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 32 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1535-2015Class IITerminatedSep 23, 2015Hyaluronic Acid Sodium 28 mg/ml + Lidocaine HCl 3 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1534-2015Class IITerminatedSep 23, 2015HCG 500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1533-2015Class IITerminatedSep 23, 2015HCG 1,200 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1532-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1531-2015Class IITerminatedSep 23, 2015HCG 4,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1530-2015Class IITerminatedSep 23, 2015HCG 3,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1529-2015Class IITerminatedSep 23, 2015HCG 2,500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1528-2015Class IITerminatedSep 23, 2015HCG 1,100 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1527-2015Class IITerminatedSep 23, 2015HCG 1,500 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1526-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1525-2015Class IITerminatedSep 23, 2015HCG 11,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1524-2015Class IITerminatedSep 23, 2015HCG 1,250 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1523-2015Class IITerminatedSep 23, 2015HCG 625 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1522-2015Class IITerminatedSep 23, 2015HCG 2,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1521-2015Class IITerminatedSep 23, 2015HCG 10,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1520-2015Class IITerminatedSep 23, 2015HCG 1,100 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1519-2015Class IITerminatedSep 23, 2015HCG 1,000 IU/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1518-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml + Methylcobalamin 500 mcg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1517-2015Class IITerminatedSep 23, 2015HCG 5,000 IU/ml + Methylcobalamin 1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1516-2015